Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Cancer J. 2009 Jul-Aug;15(4):312-8. doi: 10.1097/PPO.0b013e3181b14ec0.
Proton beam therapy (PBT) has been in use for a number of decades, though interest in PBT for localized prostate cancer has grown substantially in recent years. Protons offer the theoretical potential of achieving dose escalation and decreasing toxicity by capitalizing on unique physical dose deposition characteristics to avoid normal tissue. Although it has proven effective in a number of malignancies including as a means for dose escalation in prostate cancer, there is little published clinical data to support its comparative superiority over alternative forms of conformal radiation for prostate cancer. This review article explores the current evidence and clinical experience supporting PBT for prostate cancer, the uncertainties and controversies associated with this innovative technology, its potential economic implications, and future promise.
质子束治疗（PBT）已经使用了几十年，尽管近年来人们对局部前列腺癌的质子束治疗兴趣大大增加。质子利用独特的物理剂量沉积特性来避免正常组织，从而具有实现剂量递增和降低毒性的理论潜力。尽管它在包括前列腺癌在内的许多恶性肿瘤中已被证明是有效的，但其作为前列腺癌剂量递增手段的比较优势的临床数据很少。本文探讨了支持前列腺癌质子束治疗的当前证据和临床经验，以及与这项创新技术相关的不确定性和争议、其潜在的经济影响和未来的前景。
